MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that initial data from its ongoing
-- Management to Host Conference Call at 4:30 p.m. ET today -- MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 5, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic
MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 29, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release third quarter
MONROVIA, Calif. --(BUSINESS WIRE)--Sep. 26, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will
MONROVIA, Calif. --(BUSINESS WIRE)--Sep. 10, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Celia Eckert as
-- Management to Host Conference Call at 4:30 p.m. ET today -- MONROVIA, Calif. --(BUSINESS WIRE)--Aug. 6, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic
MONROVIA, Calif. --(BUSINESS WIRE)--Aug. 1, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will
MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 30, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release second quarter
MONROVIA, Calif. --(BUSINESS WIRE)--Jun. 27, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that Paul Foster , M.D., senior
— XmAb22841, a CTLA-4 x LAG-3 bispecific antibody, is Xencor’s third tumor microenvironment (TME) activator to enter clinical development — — Phase 1 study to explore the combination of XmAb22841 with pembrolizumab, an anti-PD-1 immunotherapy, to create triple checkpoint blockade — MONROVIA, Calif.
